Predict your next investment

Cognition Therapeutics company logo
HEALTHCARE | Drug Discovery
cogrx.com

See what CB Insights has to offer

Founded Year

2007

Stage

IPO | Alive

Total Raised

$77.3M

About Cognition Therapeutics

Cognition Therapeutics is a clinical-stage biopharmaceutical company that develops small-molecule therapeutics that address the toxic oligomeric proteins that cause synapse degeneration and trigger neurodegenerative conditions such as Alzheimer's disease.

Cognition Therapeutics Headquarter Location

2403 Sidney Street Suite 261

Pittsburgh, Pennsylvania, 15203,

United States

412-481-2210

Latest Cognition Therapeutics News

Cognition Therapeutics Announces Closing Of Full Exercise Of Underwriters' Option To Purchase Additional Shares In Connection With Initial Public Offering

Nov 15, 2021

Nov 15, 2021 7:30 AM EST Cognition Therapeutics Announces Closing Of Full Exercise Of Underwriters' Option To Purchase Additional Shares In Connection With Initial Public Offering PURCHASE, N.Y. PURCHASE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the closing of an additional 565,217 shares of its common stock following the exercise in full of the underwriters' over-allotment option in connection with Cognition's initial public offering. The over-allotment option was exercised in full two weeks prior to the end of the 45-day option period and the shares were sold at the initial public offering price of $12.00 per share, resulting in additional gross proceeds of approximately $6.8 million, before deducting underwriting discounts and commissions and other offering related expenses. Including the over-allotment, the total number of shares sold by Cognition in the offering was 4,333,333 shares, generating aggregate gross proceeds of approximately $52 million. Cognition's shares are listed on the Nasdaq Global Market under the ticker symbol "CGTX" and commenced trading on October 8, 2021. B. Riley Securities, Inc. acted as the lead bookrunning manager for the offering and Oppenheimer & Co. acted as joint bookrunning manager. Troutman Pepper Hamilton Sanders LLP is representing the Company and McGuireWoods LLP is representing the underwriters. A registration statement on Form S-1 relating to these securities was declared effective by the U.S. Securities and Exchange Commission on October 7, 2021. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from B. Riley Securities, Inc., Attention: Prospectus Department, 1300 North 17 th Street, Suite 1300, Arlington, Virginia 22209, or by telephone at (703) 312-9580, or by email at  prospectuses@brileyfin.com ; or from Oppenheimer & Co., Attention: Syndicate Prospectus Department, 85 Broad Street, 26 th Floor, New York, New York 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com . About Cognition TherapeuticsCognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, including the Company's expectations regarding the offering of the Company's shares of common stock, including as to the consummation of the offering described above and the size of the offering, are forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those identified under the heading "Risk Factors" in our final prospectus, dated October 7, 2021, that was filed with the Securities and Exchange Commission ("SEC") under File No. 333-257999, as the same may be updated or supplemented by our other filings with the SEC. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Contact Information: Cognition Therapeutics, Inc. info@cogrx.com Aline Sherwood (media)Scienta Communications asherwood@scientapr.com Lisa Sher (investors)Tiberend Strategic Advisors, Inc. lsher@tiberend.com By

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cognition Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cognition Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Cognition Therapeutics Patents

Cognition Therapeutics has filed 16 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Alzheimer's disease
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/21/2018

4/7/2020

Acetylcholinesterase inhibitors, Piperazines, Trifluoromethyl compounds, Organophosphate insecticides, Piperidines

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/21/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/7/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Acetylcholinesterase inhibitors, Piperazines, Trifluoromethyl compounds, Organophosphate insecticides, Piperidines

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Cognition Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cognition Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.